Last reviewed · How we verify
NCT00803218
Bioequivalence of Two Fluticasone Propionate 0.005% Topical Ointments
trial testing Fluticasone Propionate 0.005% Ointment-Reference Product in Healthy in 56 participants. Completed in 1 November 2002.
1 November 2002
Quick facts
| Lead sponsor | Padagis LLC |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 1 November 2002 |
| Primary completion | 1 November 2002 |
| Estimated completion | 1 November 2002 |
Drugs / interventions tested
- Fluticasone Propionate 0.005% Ointment-Reference Product — full drug profile →
- Fluticasone Propionate 0.005% Ointment-Test product — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Padagis LLC — full company profile →
Who can join
Adults 18 to 50, female only, with Healthy. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Vasoconstriction will be measured by the degree of skin blanching observed after treatment removal using a ChromaMeter
Time frame: Over the course of one day
Sponsor's own description
The purpose of this study was to compare the relative vasoconstrictive effects of test and reference topical Fluticasone Propionate 0.005% Ointments in healthy, female subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00803218
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Padagis LLC trials
Trials by the same sponsor.
- NCT05763082 — Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis · Phase 3 · completed
- NCT04944290 — To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocul · Phase 3 · completed
- NCT04155203 — To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infe · Phase 3 · completed
- NCT04024072 — To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocul · Phase 3 · completed
- NCT03393494 — Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00803218 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Padagis LLC
- Last refreshed: 7 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00803218.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing